Albion® Zinc Bisglycinate: Clinical Research & Scientific Evidence

Key Takeaways

• Albion® Zinc Bisglycinate is a chelated zinc form in which zinc is associated with two glycine molecules.
• Human studies suggest zinc bisglycinate can provide favorable absorption and bioavailability compared with some commonly used zinc forms.
• A 2007 clinical study found 43.4% greater oral zinc bioavailability with zinc bisglycinate than zinc gluconate.
• Other research has reported increases in plasma zinc and higher acute zinc uptake with zinc glycinate compared with certain other zinc forms.
• The evidence supports differences in zinc absorption and zinc status, but it does not establish that zinc bisglycinate produces superior long-term health outcomes.
• Albion®'s TRAACS® technology provides a defined chelation and manufacturing approach, but generic zinc bisglycinate research should not automatically be considered clinical research specifically on Albion®.
• Zinc is essential, but more is not necessarily better. Excessive intake can cause adverse effects and interfere with copper status.
• Overall, the research supports zinc bisglycinate as a well-studied chelated form of zinc, while the strength of evidence varies by outcome and study design.
  
  

Zinc is an essential mineral involved in numerous biological processes, including immune function, DNA synthesis, protein metabolism, and antioxidant defense. However, the form in which zinc is consumed can influence how much zinc becomes available to the body.

Zinc bisglycinate is a chelated form of zinc in which the mineral is associated with two glycine molecules. Albion® offers zinc bisglycinate as part of its branded chelated mineral portfolio, using its TRAACS® technology and ingredient-specific manufacturing and quality framework.

Human research has examined zinc bisglycinate and related zinc glycinate forms against other zinc compounds, including zinc gluconate, zinc picolinate, and zinc oxide. These studies provide useful evidence about absorption and zinc status, but those measures should not automatically be interpreted as evidence of superior long-term health outcomes.

This article examines the human clinical research on zinc bisglycinate, what the studies actually measured, and what can reasonably be concluded about Albion® zinc bisglycinate.

What Does the Research Show About Albion® Zinc Bisglycinate?

Human research shows that zinc bisglycinate can provide higher zinc exposure and improve zinc status compared with some other zinc forms, although the evidence is primarily focused on absorption and zinc-status measures rather than long-term health outcomes.

In a randomized crossover study of 12 healthy women, zinc bisglycinate produced 43.4% greater oral bioavailability  than zinc gluconate after a single 15 mg dose of elemental zinc.

Another study involving 30 young women found that zinc glycinate increased plasma zinc after six weeks of supplementation, while zinc gluconate did not produce a significant overall increase in the same measure.

These findings suggest that zinc bisglycinate and related glycinate forms can have favorable absorption or zinc-status characteristics under specific study conditions. However, the clinical evidence remains more established for bioavailability and zinc-status measures than for broader health outcomes.

What Is Albion® Zinc Bisglycinate?

Zinc bisglycinate is a chemical form of zinc in which zinc is bound to two glycine molecules. Chelation is used to create a specific mineral-amino acid complex that can influence the mineral's behavior during digestion and absorption.

Albion® identifies zinc bisglycinate as one of its chelated mineral ingredients. Its technical information describes Zinc Bisglycinate Chelate as a fully reacted chelated mineral in which zinc is bound to two glycine ligands.

It is important to distinguish three concepts:

• Zinc: the essential mineral itself.

• Zinc bisglycinate: the specific chemical form of zinc.

• Albion® zinc bisglycinate: a branded ingredient produced within Albion's ingredient and quality framework.
  
  

Albion® also uses the TRAACS® designation for its amino acid-chelated mineral system. TRAACS® stands for The Real Amino Acid Chelate System and refers to Albion's approach to amino acid mineral chelation and quality control.

For a broader explanation of Albion® Minerals, TRAACS® technology, and how chelated minerals differ from generic mineral ingredients, see The Power of Albion Minerals.

Why Does the Form of Zinc Matter?

Not all zinc compounds behave identically in the digestive tract.

The form of zinc can influence factors such as:

• Dissolution

• Interaction with other dietary components

• Absorption

• Circulating zinc concentrations

• Overall zinc status
  
  

This creates an important evidence pathway:

Supplement form → zinc absorption → zinc exposure or status → biological effects → clinical outcomes

Each step represents a different level of evidence.

A study showing greater absorption does not automatically demonstrate better immune function, fewer illnesses, improved health outcomes, or other long-term benefits.

That distinction is particularly important when interpreting mineral research.

For a broader overview of zinc bisglycinate, including its absorption characteristics, potential benefits, and comparison with other zinc forms, see our guide to Albion® Zinc Bisglycinate.

Zinc Bisglycinate Absorption: What Does the Research Show?

Zinc Bisglycinate vs Zinc Gluconate

One of the most directly relevant human studies was published by Gandia and colleagues in 2007.

The randomized crossover study included 12 healthy female volunteers. Participants received a single dose containing 15 mg of elemental zinc, provided either as zinc bisglycinate or zinc gluconate.

The researchers measured serum zinc concentrations and pharmacokinetic parameters following supplementation.

Zinc bisglycinate produced 43.4% greater oral bioavailability than zinc gluconate under the conditions of the study.

This provides direct human evidence that the chemical form of zinc can influence zinc exposure.

However, the study had several limitations:

• Only 12 participants were included.

• Participants were healthy women.

• It examined a single dose.

• It measured short-term pharmacokinetic outcomes rather than long-term health effects.
  
  

Therefore, the result supports a difference in zinc bioavailability under the studied conditions, but it does not establish that zinc bisglycinate produces superior long-term health outcomes.

Zinc Bisglycinate vs Zinc Gluconate in Young Women

A second human study examined zinc glycinate supplementation over a longer period.

DiSilvestro and colleagues studied 30 young adult women, divided into three groups receiving zinc glycinate, zinc gluconate, or placebo.

Participants receiving zinc glycinate consumed 60 mg of elemental zinc per day for six weeks.

At the end of the study, plasma zinc increased in all 10 participants receiving zinc glycinate. The zinc gluconate group did not show a statistically significant overall increase in plasma zinc.

The researchers also measured erythrocyte superoxide dismutase activity, but there was no significant change in this marker.

An important limitation is the dose. 60 mg of elemental zinc per day exceeds the adult tolerable upper intake level of 40 mg per day established by the U.S. National Institutes of Health.

Therefore, this study provides evidence about differences between zinc forms under controlled research conditions, but its dose should not be interpreted as a recommended consumer dosage.

Zinc Bisglycinate vs Zinc Picolinate and Zinc Oxide

An earlier conference abstract by DiSilvestro and Swan compared several commercially available zinc supplements, including glycinate, gluconate, picolinate, and oxide.

The study involved 12 women and used a zinc tolerance test to assess acute zinc uptake.

The researchers reported higher acute zinc uptake with the glycinate preparation compared with the other tested forms.

However, this evidence carries less weight than a full peer-reviewed clinical paper because the publication was a conference abstract and provides less methodological detail.

A 2024 narrative review of zinc forms also concluded that differences in absorption and bioavailability exist among chemical forms, while noting that the human evidence base remains limited and heterogeneous.

What Does the Overall Human Evidence Show?

The available human research points toward differences in zinc absorption and zinc status depending on the chemical form used.

The research supports zinc bisglycinate as a zinc form with favorable bioavailability under studied conditions, but the evidence is much stronger for absorption and zinc-status outcomes than for superior long-term clinical outcomes.

This distinction matters because bioavailability is an intermediate outcome. It tells us how the body handles the nutrient, but it does not by itself establish that one form produces better health outcomes over months or years.

Does Better Zinc Absorption Mean Better Health Outcomes?

Not necessarily.

Zinc itself has well-established biological functions. It is required for normal immune function, DNA and protein synthesis, cell division, wound healing, and numerous enzymatic reactions.

However, the evidence supporting these physiological roles should not be confused with evidence that a particular zinc form produces superior health outcomes.

For example, a study can show:

Higher zinc absorption

without demonstrating:

Better immune function

or:

Lower disease risk

or:

Better long-term health

The human research on zinc bisglycinate is currently much stronger at the absorption and zinc-status level than at the long-term clinical-outcome level.

What Makes Albion® Zinc Bisglycinate Scientifically Different?

The scientific distinction is primarily between the chemical form of zinc and the specific branded ingredient platform.

Human clinical studies provide evidence about zinc bisglycinate or zinc glycinate as chemical forms. Albion® adds another layer involving ingredient sourcing, chelation technology, manufacturing, specifications, and quality control.

Albion® describes its Zinc Bisglycinate Chelate as a fully reacted chelated mineral in which zinc is associated with two glycine ligands.

This means the Albion® designation does not represent a different mineral from zinc bisglycinate. Rather, it identifies a branded ingredient produced according to a particular manufacturing and quality framework.

That distinction is important when interpreting research.

A study showing that zinc bisglycinate has favorable bioavailability does not automatically prove that every branded zinc bisglycinate ingredient has identical performance.

Likewise, the presence of an Albion® trademark does not by itself establish superior clinical outcomes.

What Does TRAACS® Tell Us?

TRAACS® stands for The Real Amino Acid Chelate System.

Albion® uses TRAACS® to describe its amino acid-chelated mineral technology. Its technical materials describe mineral-amino acid complexes that undergo controlled manufacturing and analytical characterization.

Albion® technical information also discusses structural characterization techniques, including X-ray crystallography, to help characterize mineral chelate structures.

These technical data are useful for understanding the ingredient's structure and manufacturing technology.

However, technical characterization should be kept separate from clinical outcome evidence.

Technical evidence can establish what an ingredient is and how it is characterized. Human clinical evidence is needed to establish what that ingredient does in people.

Is the Research Specifically on Albion® Zinc Bisglycinate?

This is an important limitation to understand.

The strongest published human study directly comparing zinc bisglycinate with zinc gluconate identifies the test material as zinc bisglycinate.

Albion® cites this study in its technical information for Zinc Bisglycinate Chelate.

However, that does not mean every published study of zinc bisglycinate should automatically be described as a clinical trial of the branded Albion® ingredient.

The scientifically appropriate distinction is:

Human evidence for zinc bisglycinate: Supports the absorption and zinc-status characteristics of the chemical form.

Albion® technical evidence: Provides information about the branded ingredient, chelation technology, formulation, and quality framework.

Albion®-specific clinical evidence: Should only be claimed when a study clearly identifies the specific Albion® ingredient being tested.

This approach keeps the evidence accurate while still showing why ingredient sourcing matters.

What Do Clinical Studies Actually Support?

Based on the available evidence, the research supports several conclusions.

Zinc absorption

Human clinical evidence indicates that zinc bisglycinate can provide greater bioavailability than zinc gluconate under specific study conditions.

Zinc status

Human research also indicates that zinc glycinate can increase plasma zinc under certain supplementation conditions.

Differences between zinc forms

Available studies suggest that zinc absorption and bioavailability can vary according to the chemical form used.

Zinc's biological functions

The physiological importance of zinc itself is well established.

Superior long-term health outcomes

There is not sufficient evidence to conclude that zinc bisglycinate produces superior long-term health outcomes compared with other appropriate zinc forms.

Albion®-specific superiority

The available evidence does not establish that Albion® zinc bisglycinate is clinically superior to all other zinc bisglycinate ingredients.

TRAACS® structure and characterization

Albion® technical materials provide information about its chelation technology, ingredient structure, and analytical characterization.

Zinc Bisglycinate Safety and Dosage Considerations

Zinc is an essential nutrient, but more is not necessarily better.

Excessive zinc intake can cause nausea, vomiting, gastric discomfort, and other gastrointestinal effects. Chronically high zinc intake can also interfere with copper absorption and contribute to copper deficiency.

For adults, the U.S. National Institutes of Health lists a tolerable upper intake level of 40 mg of zinc per day from all sources.

This is an important distinction when reviewing clinical research.

For example, the DiSilvestro study used 60 mg of elemental zinc per day for six weeks. That dose was used as part of a research protocol and should not be interpreted as a general supplementation recommendation.

The appropriate zinc intake depends on the individual's dietary intake, age, sex, health status, and other factors.

Frequently Asked Questions

Is Albion® zinc bisglycinate better absorbed?

Human research suggests that zinc bisglycinate can have greater bioavailability than zinc gluconate under certain conditions. In one study of 12 healthy women, bisglycinate showed 43.4% greater oral bioavailability than gluconate after a single 15 mg dose.

This result should not be interpreted as proof of superior long-term health outcomes.

What does the research say about zinc bisglycinate?

Human research primarily supports differences in zinc absorption, bioavailability, and zinc status between certain zinc forms. Evidence for broader long-term clinical benefits is more limited.

Is zinc bisglycinate clinically proven to provide more health benefits?

No. The strongest evidence concerns absorption and zinc-status measures rather than broad clinical outcomes.

Is Albion® zinc bisglycinate the same as generic zinc bisglycinate?

They can share the same general chemical form, but branded ingredients can differ in source, manufacturing processes, specifications, analytical testing, and documentation.

What is TRAACS®?

TRAACS® stands for The Real Amino Acid Chelate System. It is Albion®'s branded system for amino acid-chelated mineral ingredients and associated quality and characterization processes.

Can zinc bisglycinate prevent zinc deficiency?

Zinc bisglycinate provides zinc and human studies indicate that glycinate forms can increase zinc exposure or status under studied conditions. Whether supplementation is appropriate depends on the individual's dietary intake and circumstances.

Does higher zinc absorption always mean better health?

No. Higher absorption or blood zinc levels are not the same as demonstrated improvements in long-term health outcomes.

Final Thoughts

The human evidence on zinc bisglycinate provides a useful picture of how zinc form can influence absorption and zinc status. Studies comparing bisglycinate or glycinate with other zinc compounds have found favorable results under specific research conditions, including greater bioavailability than zinc gluconate in one controlled study.

However, better absorption should not automatically be interpreted as better long-term health outcomes. The strongest evidence currently concerns zinc exposure and status rather than broad clinical benefits.

Albion® adds another layer to this discussion through its branded mineral ingredients, TRAACS® chelation technology, manufacturing framework, and technical characterization. The scientifically appropriate approach is to distinguish these ingredient-specific and technical characteristics from independent human clinical evidence.

At Just Glow, we believe science-backed ingredients and evidence-based nutrition are the foundation of long-term wellness. Understanding the evidence behind a mineral form helps you make more informed decisions about the ingredients you choose.